Neil Goldsmith
Président chez CHOSA ONCOLOGY AB
Profil
Neil Goldsmith is the founder of Biotage AB (1997), Evolva SA (2004), Evolva Holding SA (2004), Alentis Therapeutics AG (2019), and Sundew ApS (2018).
He is also the founder of Topotarget A.
Mr. Goldsmith's current jobs include Co-Chief Executive Officer at Chosa ApS (2022-present), Chairman at Chosa Oncology AB (2023-present), and Director at Biotechnology Innovation Organization, Unibio International Plc, and Double Bioventures Ltd.
Mr. Goldsmith's former jobs include Chief Executive Officer & Director at Allylix, Inc., Chief Executive Officer at Auda Pharmaceuticals ApS, Chief Executive Officer at PNA Diagnostics A, Chief Executive Officer at GX Biosystems A, Non-Executive Chairman at InSecta Ltd., Director at Quadrant Healthcare Plc, and Vice President-Business Development at Biacore AB.
Mr. Goldsmith received his undergraduate degree from Balliol College.
Postes actifs de Neil Goldsmith
| Sociétés | Poste | Début |
|---|---|---|
| CHOSA ONCOLOGY AB | Président | 01/01/2023 |
Chosa ApS
 Chosa ApS Miscellaneous Commercial ServicesCommercial Services Chosa ApS is a Danish company that provides biotechnology services. The private company is based in Copenhagen, Denmark. The CEOs are Claus Frisenberg Pedersen and Neil Goldsmith. The company was founded in 2022. | Directeur Général | 06/05/2022 |
Sundew ApS
 Sundew ApS Packaged SoftwareTechnology Services Sundew ApS targets water-borne pests and diseases. The company is based in Copenhagen, Denmark. and has subsidiaries in Ireland. The Danish company was founded in 2018 by Neil Goldsmith, Jørgen Hansen, Andy Gardiner. Giovanni Salerno has been the CEO of the company since 2021. | Fondateur | 01/03/2018 |
Double Bioventures Ltd.
 Double Bioventures Ltd. Miscellaneous Commercial ServicesCommercial Services Double Bioventures Ltd. is a British company founded in 2018 that builds non-traditional life-science companies in non-traditional ways. The private company is based in London, UK. The company focuses on identifying opportunities outside core therapeutics and developing robust business models for such businesses. The company aims to help life-science ventures play a wider role in meeting the challenges of the modern world. | Directeur/Membre du Conseil | 14/03/2018 |
Unibio International Plc
 Unibio International Plc Financial ConglomeratesFinance Unibio International Plc is a leading British sustainable protein company that specializes in producing single-cell protein for animal feed. The company is based in London, UK, and David Henstrom has been the CEO since 2021. The company has won several awards for its environmentally friendly practices, including the "Kalundborg Business Council's Green Environment and Climate Award." Unibio has participated in various exhibitions and conferences worldwide, including the "Forum for Innovations in Agriculture" in 2018 and the "Deutsche Messe Hannover" in 2018. | Directeur/Membre du Conseil | 08/03/2018 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Directeur/Membre du Conseil | - |
Anciens postes connus de Neil Goldsmith
| Sociétés | Poste | Fin |
|---|---|---|
Alentis Therapeutics AG
 Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Fondateur | 09/11/2021 |
| EVOLVA HOLDING SA | Fondateur | 06/07/2017 |
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Fondateur | 01/01/2017 |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ | - |
Formation de Neil Goldsmith
| Balliol College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BIOTAGE AB | Health Technology |
| EVOLVA HOLDING SA | Consumer Non-Durables |
| CHOSA ONCOLOGY AB | Commercial Services |
| Entreprise privées | 15 |
|---|---|
Allylix, Inc.
 Allylix, Inc. Pharmaceuticals: OtherHealth Technology Allylix, Inc. develops terpene products for flavor and fragrance, food ingredients, pharmaceuticals, agricultural, and biofuels markets. The company was founded by Joseph Chappel, Thomas E. Jurgensen, and Joseph Noel on January 4, 2005 and is headquartered in Lexington, KY. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Auda Pharmaceuticals ApS
 Auda Pharmaceuticals ApS Miscellaneous Commercial ServicesCommercial Services Part of Phytera, Inc., Auda Pharmaceuticals ApS provides proprietary combinatorial chemistry technologies. Auda Pharmaceuticals was acquired by Phytera, Inc. from Danish Development Finance Corp on March 17, 1997. | Commercial Services |
Topotarget A/S
 Topotarget A/S Pharmaceuticals: MajorHealth Technology Topotarget A/S is a biotechnology company that is engaged in the development and commercialization of novel drugs for the treatment of cancer. Its product belinostat is a novel histone deacetylase inhibitor which is used for cancer patients. The company was founded by Peter Buhl Jensen and Maxwell Sehested in 2000 and is headquartered in Copenhagen, Denmark. | Health Technology |
Quadrant Healthcare Plc
 Quadrant Healthcare Plc Pharmaceuticals: MajorHealth Technology Part of Perrigo Co. Plc, Quadrant Healthcare Plc is a British company that researches, develops, and formulates drugs. The company is based in Cambridge, UK. Quadrant Healthcare was acquired by Elan Europe Ltd. on January 11, 2001 for $69.60 million. | Health Technology |
PNA Diagnostics A/S
 PNA Diagnostics A/S Medical SpecialtiesHealth Technology PNA-Diagnostics A/S manufactures medical diagnostic equipment. The firm is a subsidiary of Applera Corp. The company is headquartered in Copenhagen, Denmark | Health Technology |
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Commercial Services |
InSecta Ltd.
 InSecta Ltd. Miscellaneous Commercial ServicesCommercial Services InSecta is the world's leading commercial developer of the Sterile Insect Technique (SIT). SIT provides a practical, cost-effective solution to the problems facing the fruit production industry - it allows insect pests to be controlled, and provides an effective and ecologically beneficial alternative to chemical control methods. InSecta is currently focused on controlling Medfly around the Mediterranean basin. Medfly is a major economic pest of fruit production, especially citrus. InSecta provides its clients with the goods and services necessary to establish effective SIT control at all stages of the control process: definition; planning; implementation and operation. | Commercial Services |
| GX Biosystems A/S | |
| Biacore AB | |
Alentis Therapeutics AG
Alentis Therapeutics AG Pharmaceuticals: MajorHealth Technology Alentis Therapeutics AG develops novel medications to treat advanced liver diseases and cancers. The company was founded by Neil Goldsmith on March 1, 2019 and is headquartered in Basel, Switzerland. | Health Technology |
Unibio International Plc
Unibio International Plc Financial ConglomeratesFinance Unibio International Plc is a leading British sustainable protein company that specializes in producing single-cell protein for animal feed. The company is based in London, UK, and David Henstrom has been the CEO since 2021. The company has won several awards for its environmentally friendly practices, including the "Kalundborg Business Council's Green Environment and Climate Award." Unibio has participated in various exhibitions and conferences worldwide, including the "Forum for Innovations in Agriculture" in 2018 and the "Deutsche Messe Hannover" in 2018. | Finance |
Double Bioventures Ltd.
Double Bioventures Ltd. Miscellaneous Commercial ServicesCommercial Services Double Bioventures Ltd. is a British company founded in 2018 that builds non-traditional life-science companies in non-traditional ways. The private company is based in London, UK. The company focuses on identifying opportunities outside core therapeutics and developing robust business models for such businesses. The company aims to help life-science ventures play a wider role in meeting the challenges of the modern world. | Commercial Services |
Sundew ApS
Sundew ApS Packaged SoftwareTechnology Services Sundew ApS targets water-borne pests and diseases. The company is based in Copenhagen, Denmark. and has subsidiaries in Ireland. The Danish company was founded in 2018 by Neil Goldsmith, Jørgen Hansen, Andy Gardiner. Giovanni Salerno has been the CEO of the company since 2021. | Technology Services |
Chosa ApS
Chosa ApS Miscellaneous Commercial ServicesCommercial Services Chosa ApS is a Danish company that provides biotechnology services. The private company is based in Copenhagen, Denmark. The CEOs are Claus Frisenberg Pedersen and Neil Goldsmith. The company was founded in 2022. | Commercial Services |